Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA

White Matter Changes in Patients with Friedreich Ataxia after Treatment with Erythropoietin

BACKGROUND AND PURPOSE:

Erythropoietin (EPO) has received growing attention because of its neuroregenerative properties. Preclinical and clinical evidence supports its therapeutic potential in brain conditions like stroke, multiple sclerosis, and schizophrenia. Also, in Friedreich ataxia, clinical improvement after EPO therapy was shown. The aim of this study was to assess possible therapy-associated brain white matter changes in these patients.

Read More: White Matter Changes in Patients with Friedreich Ataxia after Treatment with Erythropoietin


About the Author

Jen Farmer

Jen Farmer

Executive Director

SHARE

FacebookTwitterLinkedinShare on Google+
Family B.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News